ArticleBMC gastroenterology2026
Personalized assessment of hyperuricemia probability in metabolic dysfunction-associated steatotic liver disease: construction and multicenter validation of a clinical nomogram.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease is increasingly recognized as a precursor to secondary hyperuricemia, significantly exacerbating metabolic burden. However, reliable tools for early risk stratification in MASLD patients remain limited. This study aimed to develop and validate a robust machine learning-based model to identify factors associated with concurrent hyperuricemia and develop a diagnostic nomogram for MASLD patients.
methodsA multicenter retrospective study was conducted involving 530 participants from two independent hospitals. The Least Absolute Shrinkage and Selection Operator regression was employed to screen characteristic variables. Seven machine learning algorithms, including Logistic Regression, Random Forest, and XGBoost, were constructed and compared. A quantitative nomogram was subsequently developed based on the optimal model.
resultsSix independent risk factors were identified: gender, body mass index, gamma-glutamyl transferase, serum creatinine concentration, serum triglycerides concentration, and the TyG index. Among the evaluated algorithms, the logistic regression model exhibited the superior balance of robustness and interpretability, achieving an area under the curve of 0.93 in the internal validation set and 0.67 in the external validation cohort. The constructed nomogram demonstrated satisfactory calibration and significant clinical utility, as confirmed by decision curve analysis, effectively distinguishing high-risk individuals across diverse populations.
conclusionThe novel logistic regression-based nomogram provides a practical, accurate, and cost-effective tool for the personalized risk assessment of concurrent hyperuricemia in MASLD patients, facilitating informed clinical decision-making and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.